Abstract
Screening all colorectal cancer (CRC) tumors for Lynch syndrome (LS) was first recommended in 2009. Universal tumor screening (UTS) for LS among all newly diagnosed cases of colorectal (CRC) and endometrial (EC) cancers continues to be a cost-effective genomic medicine intervention with top-tier evidence for reducing cancer morbidity and mortality that is recommended by multiple professional organizations. After over a decade of this recommendation, most individuals with LS remain undiagnosed. One reason is the variable implementation of UTS programs in healthcare systems.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
